BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38253970)

  • 21. Prognostic and predictive biomarkers in central nervous system tumours: the molecular state of play.
    Satgunaseelan L; Sy J; Shivalingam B; Sim HW; Alexander KL; Buckland ME
    Pathology; 2024 Mar; 56(2):158-169. PubMed ID: 38233331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.
    Joseph NM; Phillips J; Dahiya S; M Felicella M; Tihan T; Brat DJ; Perry A
    Mod Pathol; 2013 Mar; 26(3):315-26. PubMed ID: 23041832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PHOX2B is a reliable immunomarker in distinguishing peripheral neuroblastic tumours from CNS embryonal tumours.
    Alexandrescu S; Paulson V; Dubuc A; Ligon A; Lidov HG
    Histopathology; 2018 Sep; 73(3):483-491. PubMed ID: 29758594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of oligodendrocyte differentiation by Olig2 and Sox10: evidence for reciprocal interactions and dosage-dependent mechanisms.
    Liu Z; Hu X; Cai J; Liu B; Peng X; Wegner M; Qiu M
    Dev Biol; 2007 Feb; 302(2):683-93. PubMed ID: 17098222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisation.
    Auffret L; Ajlil Y; Tauziède-Espariat A; Kergrohen T; Puiseux C; Riffaud L; Blouin P; Bertozzi AI; Leblond P; Blomgren K; Froelich S; Picca A; Touat M; Sanson M; Beccaria K; Blauwblomme T; Dangouloff-Ros V; Boddaert N; Varlet P; Debily MA; Grill J; Castel D
    Acta Neuropathol; 2023 Dec; 147(1):2. PubMed ID: 38066305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OLIG2 as a specific marker of oligodendroglial tumour cells.
    Marie Y; Sanson M; Mokhtari K; Leuraud P; Kujas M; Delattre JY; Poirier J; Zalc B; Hoang-Xuan K
    Lancet; 2001 Jul; 358(9278):298-300. PubMed ID: 11498220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligodendrocyte origin and development in the zebrafish visual system.
    Santos-Ledo A; Pérez-Montes C; DeOliveira-Mello L; Arévalo R; Velasco A
    J Comp Neurol; 2023 Mar; 531(4):515-527. PubMed ID: 36477827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence of ambiguous differentiation and mTOR pathway dysregulation in subependymal giant cell astrocytoma.
    Barrows BD; Rutkowski MJ; Gültekın SH; Parsa AT; Tıhan T
    Turk Patoloji Derg; 2012; 28(2):95-103. PubMed ID: 22627626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of oligodendrocytes from adult human olfactory epithelial-derived progenitors by transcription factors.
    Zhang X; Cai J; Klueber KM; Guo Z; Lu C; Qiu M; Roisen FJ
    Stem Cells; 2005 Mar; 23(3):442-53. PubMed ID: 15749939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical comparative analysis of GFAP, MAP - 2, NOGO - A, OLIG - 2 and WT - 1 expression in WHO 2016 classified neuroepithelial tumours and their prognostic value.
    Schwab DE; Lepski G; Borchers C; Trautmann K; Paulsen F; Schittenhelm J
    Pathol Res Pract; 2018 Jan; 214(1):15-24. PubMed ID: 29258767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can oligodendrocyte transcriptional factor-2 (Olig2) be used as an alternative for 1p/19q co-deletions to distinguish oligodendrogliomas from other glial neoplasms?
    Kurdi M; Alkhatabi H; Butt N; Albayjani H; Aljhdali H; Mohamed F; Alsinani T; Baeesa S; Almuhaini E; Al-Ghafari A; Hakamy S; Faizo E; Bahakeem B
    Folia Neuropathol; 2021; 59(4):350-358. PubMed ID: 35114775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predominant expression of OLIG2 over ID2 in oligodendroglial tumors.
    Mikami S; Hirose Y; Yoshida K; Kawase T; Ohnishi A; Nagashima K; Mukai M; Okada Y; Ikeda E
    Virchows Arch; 2007 May; 450(5):575-84. PubMed ID: 17431671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
    Jain S; Gupta P; Shankar KB; Singh R; Siraj F
    J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gain of Olig2 function in oligodendrocyte progenitors promotes remyelination.
    Wegener A; Deboux C; Bachelin C; Frah M; Kerninon C; Seilhean D; Weider M; Wegner M; Nait-Oumesmar B
    Brain; 2015 Jan; 138(Pt 1):120-35. PubMed ID: 25564492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
    Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
    Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular pathology of paediatric central nervous system tumours.
    Chiang JC; Ellison DW
    J Pathol; 2017 Jan; 241(2):159-172. PubMed ID: 27701736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SOX10 Distinguishes Pilocytic and Pilomyxoid Astrocytomas From Ependymomas but Shows No Differences in Expression Level in Ependymomas From Infants Versus Older Children or Among Molecular Subgroups.
    Kleinschmidt-DeMasters BK; Donson AM; Richmond AM; Pekmezci M; Tihan T; Foreman NK
    J Neuropathol Exp Neurol; 2016 Apr; 75(4):295-8. PubMed ID: 26945037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lineage-Restricted OLIG2-RTK Signaling Governs the Molecular Subtype of Glioma Stem-like Cells.
    Kupp R; Shtayer L; Tien AC; Szeto E; Sanai N; Rowitch DH; Mehta S
    Cell Rep; 2016 Sep; 16(11):2838-2845. PubMed ID: 27626655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
    Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
    J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.